Indian Pharmacopoeia Commission (IPC) and Andhra Pradesh MedTech Zone (AMTZ) Organise National Meet on Strengthening Pharmacovigilance and Materiovigilance in India at Visakhapatnam

1. At a Glance

First-ever National Annual Meet of PvPI (Pharmacovigilance Programme of India) and MvPI (Materiovigilance Programme of India) Regional Centres, jointly hosted by IPC and AMTZ at Visakhapatnam, 27–28 February 2026 [S1].
Marks institutional convergence of drug safety and medical-device safety surveillance under one national framework — a recurring theme in GS-II governance and GS-III S&T/health [S1].

Two-day National Meet at AMTZ, Visakhapatnam concluded 28 Feb 2026, organised by IPC (MoHFW) with Andhra Pradesh MedTech Zone [S1].
ADR PvPI 2.0 Mobile Application launched to enable real-time Adverse Drug Reaction reporting and citizen/HCP engagement [S1].
India's rise from rank 123 (2009-14) to 8th globally in 2025 in WHO's pharmacovigilance database (VigiBase) contributions [S2].

Indian Pharmacopoeia Commission (IPC) — autonomous body, Ministry of Health & Family Welfare, headquartered at Ghaziabad, UP; publishes the Indian Pharmacopoeia (10th edition released 2025 by Sh. J.P. Nadda) [S2][S3].
PvPI — National Coordination Centre shifted to IPC, Ghaziabad in 2010; monitors Adverse Drug Reactions through ADR Monitoring Centres (AMCs) [S2].
MvPI — launched to monitor adverse events from medical devices via Medical Device Monitoring Centres (MDMCs) under IPC [S1].
AMTZ — India's first integrated medical-device manufacturing zone, set up by Govt. of Andhra Pradesh at Visakhapatnam [S1].
5th National Pharmacovigilance Week inaugurated by IPC in 2025, focus on patient safety & ADR reporting [S4].

Parent Ministry: Ministry of Health and Family Welfare [S1].
Nodal Body: Indian Pharmacopoeia Commission, Ghaziabad [S2].
PvPI National Coordination Centre: IPC, Ghaziabad [S2].
MvPI Coordination: IPC (in collaboration with CDSCO) [S1].
Host City of Meet: Visakhapatnam, Andhra Pradesh; venue – AMTZ campus [S1].
Statutory base for drug/device regulation: Drugs and Cosmetics Act, 1940; Medical Devices Rules, 2017 (general UPSC reference) [S1].
App Launched: ADR PvPI 2.0 Mobile Application [S1].
India's global PV ranking: 8th worldwide in WHO pharmacovigilance database, 2025 [S2].

Scientific/Technological: ADR PvPI 2.0 enables real-time data capture; integration of AMCs + MDMCs into a digital surveillance grid [S1].
Administrative/Governance: Improves coordination between regulators (CDSCO), healthcare institutions, AMCs, and MDMCs — addresses fragmented post-market surveillance [S1].
Social/Public Health: Reinforces patient safety, rational drug use, reduces iatrogenic harm; aligns with Universal Health Coverage goals [S4].
Economic/Industrial: AMTZ collaboration links safety regulation to India's medical-device manufacturing ambitions under the PLI for medical devices and Atmanirbhar Bharat [S1].
Geopolitical: Strengthens India's contribution to WHO–UMC (Uppsala Monitoring Centre) VigiBase, raising credibility of "Pharmacy of the World" tag [S2].

Feb 2026: First National Annual Meet of PvPI & MvPI Regional Centres at Visakhapatnam; ADR PvPI 2.0 app launched [S1].
2025: Union Health Minister J.P. Nadda released 10th Edition of Indian Pharmacopoeia [S3].
2025: IPC signed MoUs with Bihar, Maharashtra and Mizoram State Pharmacy Councils for medicine safety [S5].
2025: IPC signed three MoUs with Nagaland (Medical Council, NSDCA, State Pharmacy Council) — first such MoU with any State Medical Council [S2].
2025: IPC MoUs with Pharmaceuticals & Medical Devices Bureau of India (PMBI) and NIPER Hajipur [S6].
Nov 2025: 5th National Pharmacovigilance Week observed [S4].

IPC is headquartered at Ghaziabad, Uttar Pradesh under MoHFW [S2].
PvPI National Coordination Centre = IPC Ghaziabad (since 2010) [S2].
MvPI monitors medical device adverse events, not drugs [S1].
AMTZ is located at Visakhapatnam, Andhra Pradesh — India's first medical device manufacturing park [S1].
App launched at the Meet: ADR PvPI 2.0 [S1].
India's rank in WHO pharmacovigilance database in 2025 = 8th (up from 123rd in 2009–14) [S2].
10th Edition of Indian Pharmacopoeia released in 2025 by J.P. Nadda [S3].
ADR reporting under PvPI is fed into WHO-UMC VigiBase [S2].
AMCs = Adverse Drug Reaction Monitoring Centres; MDMCs = Medical Device Monitoring Centres [S1].
The Meet was the first annual national meet of PvPI + MvPI Regional Centres [S1].

GS-II: Governance — Issues relating to development and management of Health; statutory & regulatory bodies.
GS-III: Science & Technology — Indigenisation; Awareness in S&T (biotech, pharma).
Possible question stems: 1. "Post-market surveillance of drugs and medical devices is the missing pillar of India's health regulatory architecture. Discuss in light of PvPI and MvPI." 2. "Examine the institutional role of the Indian Pharmacopoeia Commission in ensuring drug quality and patient safety in India." 3. "How can convergence of pharmacovigilance and materiovigilance strengthen India's ambitions as the 'Pharmacy of the World'?"

IPC is under MoHFW, not Department of Pharmaceuticals (which is under Ministry of Chemicals & Fertilizers).
PvPI ≠ MvPI: drugs vs medical devices; both coordinated by IPC, but MvPI works with CDSCO too.
IPC is at Ghaziabad, not Delhi or Hyderabad.
AMTZ is an Andhra Pradesh state-government initiative, not a Central PSU.
Indian Pharmacopoeia (IP) is distinct from Ayurvedic/Homoeopathic Pharmacopoeia (under Ministry of Ayush).

[S1] IPC and AMTZ Organise National Meet on Pharmacovigilance and Materiovigilance, Visakhapatnam — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2233933&reg=1&lang=1 — (tier 1)
[S2] IPC signs 3 MoUs with Nagaland Medical Council, NSDCA and Nagaland State Pharmacy Council — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2195787&reg=3&lang=1 — (tier 1)
[S3] Union Health Minister releases 10th Edition of Indian Pharmacopoeia — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2210754&reg=3&lang=2 — (tier 1)
[S4] IPC inaugurates 5th National Pharmacovigilance Week — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2167578 — (tier 1)
[S5] IPC Signs MoUs with Bihar, Maharashtra and Mizoram State Pharmacy Councils — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2260365&reg=3&lang=2 — (tier 1)
[S6] IPC Signs MoUs with PMBI and NIPER Hajipur — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2255190&reg=3&lang=2 — (tier 1)